Adicet Bio, Inc. — Form 8-K summary
Reporting date: September 28, 2026. The filing reports preliminary Phase 1 data for prula-cel (formerly ADI-001) in systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Data cutoff was August 28, 2026.
Business and clinical update
Adicet is a clinical-stage biotechnology company. The 8-K announces preliminary clinical results and planned development steps; it does not provide financial statements or financial performance metrics.
| Measure | Reported result |
|---|---|
| Patients and follow-up | 22 efficacy-evaluable patients (16 with LN and 6 with extra-renal SLE), followed for 6–21 months; 24 patients were safety-evaluable. |
| 12-month efficacy | 50% of evaluable LN patients achieved complete renal response (CRR); 54% of evaluable patients achieved DORIS remission. Reported 12-month responses remained ongoing at 12–21 months, with one noted exception. |
| Baseline disease and prior treatment | Mean baseline SLEDAI-2K was 13; mean baseline UPCR among LN patients was 2.8. All patients had received at least three prior therapies; 71% had received four or more. |
| Safety | No CRS above Grade 2; Grade 1 or 2 CRS occurred in 25%. No dose-limiting toxicities, IEC-HS, ICANS, or graft-versus-host disease. Infections occurred in 54%, with Grade 3 or higher infections in 8.3%. |
| Other reported findings | All patients discontinued immunosuppressants; all but one tapered background steroids to 5 mg or less prednisone equivalent. All 22 efficacy-evaluable patients had undetectable CD19+ B cells. Among baseline-positive patients, 10 of 11 had reduced anti-dsDNA antibodies; 9 of 10 with low baseline complement showed complement recovery. |
Plans and outlook
Adicet says it has aligned with the FDA on a single-arm pivotal study in LN patients with inadequate response to at least two immunosuppressants. The study is expected to enroll a double-digit number of patients, with CRR at 12 months as the primary efficacy endpoint. The company plans to begin study start-up activities in the fourth quarter of 2026 and discuss with the FDA whether to include patients with non-renal SLE. These plans and timelines are forward-looking and are not assurances of study initiation, enrollment, or results.
- Fourth quarter 2026: initiate pivotal-study start-up activities and discuss study population with the FDA.
- First half 2027: anticipated systemic sclerosis clinical data update.
- Mid-2027: anticipated LN/SLE clinical data update.
The company estimates approximately 35,000 LN patients and 35,000 patients with non-renal SLE involving organ- or life-threatening disease in the United States, and expects rapid pivotal-study enrollment. These are company estimates and expectations.
Financials, changes, and risks
This 8-K contains no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and provides no comparable-period financial results. It therefore does not establish material financial changes versus a prior period.
Results are preliminary and based on a limited patient population with differing follow-up durations. The filing cautions that interim clinical results may not predict future results; studies may not demonstrate adequate safety or efficacy; regulatory processes and timelines are uncertain; and manufacturing, product release, capital-raising, and operational risks could affect development. The company also notes that outpatient suitability and future regulatory alignment remain subject to expectations and risks. Items under Regulation FD disclosure are furnished, not deemed filed for purposes of Exchange Act Section 18, except as expressly incorporated by reference.
Investor verification priorities
- Review the full press release and webcast presentation (Exhibits 99.1 and 99.2) for endpoint definitions, denominators, patient-level follow-up, and the noted exception to ongoing responses.
- Verify how efficacy-evaluable and safety-evaluable populations differ and whether additional follow-up changes the preliminary response or safety profile.
- Track FDA discussions, final pivotal-study design and eligibility, and whether non-renal SLE is included.
- Monitor study initiation, enrollment pace, and the timing and completeness of the promised clinical updates.
- Consult Adicet’s latest periodic filings for financial condition, cash runway, financing needs, and fuller risk-factor disclosure; this 8-K does not provide those financial details.